 Grifols MCE: GRF, MCE: GRF.P, NASDAQ: GRFS, a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing peoples health and well-being, today announced it has delivered the first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials. 